| Lisa Lynn Maher, ARNP | |
|
419 East Donald Street, Waterloo, IA 50703-1223 | |
| (319) 236-1911 | |
| (319) 287-5832 |
| Full Name | Lisa Lynn Maher |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 13 Years |
| Location | 419 East Donald Street, Waterloo, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003054305 | NPI | - | NPPES |
| 1003054305 | Medicaid | IA | |
| 1003054305 | Other | IA | WELLMARK BCBS |
| P00704358 (PTAN) | Other | IA | RR MEDICARE |
| 421417307-UZ | Other | IA | UHC/RIVER VALLEY/JD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | A114046 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Allen Hospital | Waterloo, IA | Hospital |
| Gundersen Palmer Lutheran Hospital And Clinics | West union, IA | Hospital |
| Waverly Health Center | Waverly, IA | Hospital |
| Community Memorial Hospital Medical Center | Sumner, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allen Memorial Hospital Corporation | 4284546045 | 99 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.
Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).
"We don't honor God when 4,500 children die every day - but they do - from the lack of something so simple, each of us takes it for granted: a safe glass of water," Rabbi Jack Bemporad, executive director of the Center for Interreligious Understanding, and journalist Susan Barnett write in Huffington Post's "Religion" blog.
Surgeons at the University of Illinois Medical Center at Chicago performed robotic-assisted surgery on a 12-year-old Chicago boy with a rare swallowing disorder called achalasia.
› Verified 8 days ago
| Entity Name | Cedar Valley Medical Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497794242 PECOS PAC ID: 1759291487 Enrollment ID: O20031208000462 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.
Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).
"We don't honor God when 4,500 children die every day - but they do - from the lack of something so simple, each of us takes it for granted: a safe glass of water," Rabbi Jack Bemporad, executive director of the Center for Interreligious Understanding, and journalist Susan Barnett write in Huffington Post's "Religion" blog.
Surgeons at the University of Illinois Medical Center at Chicago performed robotic-assisted surgery on a 12-year-old Chicago boy with a rare swallowing disorder called achalasia.
› Verified 8 days ago
| Entity Name | Allen Memorial Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891772927 PECOS PAC ID: 4284546045 Enrollment ID: O20031211000480 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.
Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).
"We don't honor God when 4,500 children die every day - but they do - from the lack of something so simple, each of us takes it for granted: a safe glass of water," Rabbi Jack Bemporad, executive director of the Center for Interreligious Understanding, and journalist Susan Barnett write in Huffington Post's "Religion" blog.
Surgeons at the University of Illinois Medical Center at Chicago performed robotic-assisted surgery on a 12-year-old Chicago boy with a rare swallowing disorder called achalasia.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lisa Lynn Maher, ARNP Po Box 2758, 4150 Kimball Ave, Waterloo, IA 50704-2758 Ph: (319) 235-5390 | Lisa Lynn Maher, ARNP 419 East Donald Street, Waterloo, IA 50703-1223 Ph: (319) 236-1911 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.
Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).
"We don't honor God when 4,500 children die every day - but they do - from the lack of something so simple, each of us takes it for granted: a safe glass of water," Rabbi Jack Bemporad, executive director of the Center for Interreligious Understanding, and journalist Susan Barnett write in Huffington Post's "Religion" blog.
Surgeons at the University of Illinois Medical Center at Chicago performed robotic-assisted surgery on a 12-year-old Chicago boy with a rare swallowing disorder called achalasia.
› Verified 8 days ago
Evans Komen, DNP,PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2750 Saint Francis Dr, Waterloo, IA 50702 Phone: 319-272-8922 Fax: 319-272-8929 | |
Dianna Kay Magginetti, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 905 Franklin St, Waterloo, IA 50703 Phone: 319-874-3000 | |
Irmela Salihovic, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2710 Saint Francis Dr Ste 320, Waterloo, IA 50702 Phone: 319-272-5000 Fax: 319-272-8072 | |
Ms. Amanda L. Vervaecke, A.R.N.P. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1825 Logan Ave, Wound & Ostomy Clinic, Waterloo, IA 50703 Phone: 319-235-3121 Fax: 319-226-2113 | |
Mr. Dieter J Boxmann, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 146 W Dale St, Suite 101, Waterloo, IA 50703 Phone: 319-233-3351 Fax: 319-233-3132 | |
Marcia A Rellihan, D.O. Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3421 W 9th St, Suite G4500, Waterloo, IA 50702 Phone: 319-233-8865 Fax: 319-272-0400 |